Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 7/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 7/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 7/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 7/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL29358207 | 1.00 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL14126977 | 1.00 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL18429 | 1.00 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL133595 | 0.99 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL2506559 | 0.99 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL1041250 | 0.99 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Perphenazine SCHEMBL28086447 | 0.94 | MAPT (0.91) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Perphenazine SCHEMBL5307579 | 0.94 | MAPT (0.91) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL10891828 | 0.93 | MAPT (0.90) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| SCHEMBL13485632 | 0.93 | MAPT (0.86) | DRD2MAPTMAPK1ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096671-B1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4028010-B1 | VS-6063 IN COMBINATION WITH CH5126766 FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260034128-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2026-02-05 | — | — | US | disclosed |
| US-20260030745-A1 | Oncological Foundation Models, Systems, and Methods | PICTURE HEALTH INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12509450-B2 | Solid forms of a dual RAF/MEK inhibitor | VERASTEM, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250388691-A1 | METHODS FOR TREATING LYMPHOMA | XENCOR INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250290934-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | CYRANO THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | disclosed |
| US-20250228963-A1 | HYDROGEL PRODRUG FOR TREATMENT | VIKING SCIENTIFIC, INC | 2025-07-17 | — | — | US | disclosed |
| CN-114630667-A | Combination of VS-6063 and CH5126766 for the treatment of cancer | 癌症研究所：皇家癌症医院 | 2022-06-14 | — | — | CN | disclosed |
| US-20220178947-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | CYRANO THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-108473565-B | CTLA4 binding agents | 默沙东公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11331395-B2 | Hydrogel prodrug for treatment | VIKING SCIENTIFIC, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022015736-A9 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11311583-B2 | Treatment methods using adenovirus | Vascular Biogenetics Ltd. (IL) | 2022-04-26 | — | — | US | disclosed |
| CN-108473585-B | PD1 and/or LAG3 binding agents | 默沙东公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114209841-A | Therapeutic compositions, combinations and methods of use | 维瑞斯特姆股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20220031698-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260030745-A1 | Oncological Foundation Models, Systems, and Methods | BRCA1, TP53, MKI67 | DRD2 4256/4885MAPT 1144/4885MAPK1 1923/4885 |
| US-20260034128-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | PTK2, CTTN, MAP2K2 | DRD2 2391/4885MAPT 3090/4885MAPK1 55/4885 |
| US-20250388691-A1 | METHODS FOR TREATING LYMPHOMA | IGLV6-57, BCL6, MALT1 | DRD2 64/4885MAPT 3971/4885MAPK1 1957/4885 |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | DRD2 3645/4885MAPT 3038/4885MAPK1 243/4885 |
| US-20220031698-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | BRAF, PTK2, NRAS | DRD2 4622/4885MAPT 2799/4885MAPK1 130/4885 |
| US-12509450-B2 | Solid forms of a dual RAF/MEK inhibitor | BRAF, MAP2K2, MAP2K1 | DRD2 976/4885MAPT 2971/4885MAPK1 12/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | DRD2 4742/4885MAPT 2171/4885MAPK1 2950/4885 |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | DRD2 18/4885MAPT 291/4885MAPK1 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.